NCT00463385 - A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 1, 2007

Primary Completion Date

May 1, 2009

Study Completion Date

December 31, 2013

Conditions

Myelofibrosis With Myeloid MetaplasiaMyeloid MetaplasiaMyelofibrosis

Interventions

DRUG

Pomalidomide

DRUG

Prednisone

Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day.

DRUG

Placebo to pomalidomide

Matching pomalidomide placebo tablets

DRUG

Placebo to prednisone

Matching prednisone placebo tablets

Trial Locations (11)

10021

New York Presbyterian HospitalWeill Medical College of Cornell University, New York

27100

Fondazione IRCCS Policlinico San Matteo, Pavia

IRCCS Policlinico S. Matteo, Pavia

55905

Mayo Clinic, Rochester

77030

MD Anderson Cancer Center Leukemia Department, Houston

90095

UCLA School of Medicine Hematology/Oncology, Los Angeles

10021-6007

Memorial Sloan-Kettering Cancer Center, New York

98109-4417

Fred Hutchinson Cancer Research Center, Seattle

A-1090

Medical University of Vienna, Department of Internal Medicine, Hematology, Vienna

08036

Hematology DepartmentHospital Clinic, Barcelona

S10 2JF

Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Trust, Sheffield